416 related articles for article (PubMed ID: 24899149)
1. Osteopontin as a therapeutic target for cancer.
Bandopadhyay M; Bulbule A; Butti R; Chakraborty G; Ghorpade P; Ghosh P; Gorain M; Kale S; Kumar D; Kumar S; Totakura KV; Roy G; Sharma P; Shetti D; Soundararajan G; Thorat D; Tomar D; Nalukurthi R; Raja R; Mishra R; Yadav AS; Kundu GC
Expert Opin Ther Targets; 2014 Aug; 18(8):883-95. PubMed ID: 24899149
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia-driven osteopontin contributes to breast tumor growth through modulation of HIF1α-mediated VEGF-dependent angiogenesis.
Raja R; Kale S; Thorat D; Soundararajan G; Lohite K; Mane A; Karnik S; Kundu GC
Oncogene; 2014 Apr; 33(16):2053-64. PubMed ID: 23728336
[TBL] [Abstract][Full Text] [Related]
3. Functional characterization of stromal osteopontin in melanoma progression and metastasis.
Kumar S; Sharma P; Kumar D; Chakraborty G; Gorain M; Kundu GC
PLoS One; 2013; 8(7):e69116. PubMed ID: 23935934
[TBL] [Abstract][Full Text] [Related]
4. Osteopontin signaling upregulates cyclooxygenase-2 expression in tumor-associated macrophages leading to enhanced angiogenesis and melanoma growth via α9β1 integrin.
Kale S; Raja R; Thorat D; Soundararajan G; Patil TV; Kundu GC
Oncogene; 2014 May; 33(18):2295-306. PubMed ID: 23728342
[TBL] [Abstract][Full Text] [Related]
5. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
Gacche RN; Meshram RJ
Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
[TBL] [Abstract][Full Text] [Related]
6. The potential of class 3 semaphorins as both targets and therapeutics in cancer.
Mishra R; Kumar D; Tomar D; Chakraborty G; Kumar S; Kundu GC
Expert Opin Ther Targets; 2015 Mar; 19(3):427-42. PubMed ID: 25434284
[TBL] [Abstract][Full Text] [Related]
7. Osteopontin: it's role in regulation of cell motility and nuclear factor kappa B-mediated urokinase type plasminogen activator expression.
Das R; Philip S; Mahabeleshwar GH; Bulbule A; Kundu GC
IUBMB Life; 2005 Jun; 57(6):441-7. PubMed ID: 16012053
[TBL] [Abstract][Full Text] [Related]
8. Silencing of osteopontin promotes the radiosensitivity of breast cancer cells by reducing the expression of hypoxia inducible factor 1 and vascular endothelial growth factor.
Yang L; Zhao W; Zuo WS; Wei L; Song XR; Wang XW; Zheng G; Zheng MZ
Chin Med J (Engl); 2012 Jan; 125(2):293-9. PubMed ID: 22340562
[TBL] [Abstract][Full Text] [Related]
9. The role of Osteopontin in tumor metastasis.
Wai PY; Kuo PC
J Surg Res; 2004 Oct; 121(2):228-41. PubMed ID: 15501463
[TBL] [Abstract][Full Text] [Related]
10. The multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis.
Chakraborty G; Jain S; Behera R; Ahmed M; Sharma P; Kumar V; Kundu GC
Curr Mol Med; 2006 Dec; 6(8):819-30. PubMed ID: 17168734
[TBL] [Abstract][Full Text] [Related]
11. Interactions between osteopontin and vascular endothelial growth factor: Implications for cancer.
Ramchandani D; Weber GF
Biochim Biophys Acta; 2015 Apr; 1855(2):202-22. PubMed ID: 25732057
[TBL] [Abstract][Full Text] [Related]
12. Lentiviral-mediated siRNA targeted against osteopontin suppresses the growth and metastasis of gastric cancer cells.
Wang ZM; Cui YH; Li W; Chen SY; Liu TS
Oncol Rep; 2011 Apr; 25(4):997-1003. PubMed ID: 21286666
[TBL] [Abstract][Full Text] [Related]
13. The role of osteopontin in the progression of solid organ tumour.
Zhao H; Chen Q; Alam A; Cui J; Suen KC; Soo AP; Eguchi S; Gu J; Ma D
Cell Death Dis; 2018 Mar; 9(3):356. PubMed ID: 29500465
[TBL] [Abstract][Full Text] [Related]
14. Osteopontin at the Crossroads of Inflammation and Tumor Progression.
Castello LM; Raineri D; Salmi L; Clemente N; Vaschetto R; Quaglia M; Garzaro M; Gentilli S; Navalesi P; Cantaluppi V; Dianzani U; Aspesi A; Chiocchetti A
Mediators Inflamm; 2017; 2017():4049098. PubMed ID: 28769537
[TBL] [Abstract][Full Text] [Related]
15. Activation of JAK2/STAT3 signaling by osteopontin promotes tumor growth in human breast cancer cells.
Behera R; Kumar V; Lohite K; Karnik S; Kundu GC
Carcinogenesis; 2010 Feb; 31(2):192-200. PubMed ID: 19926637
[TBL] [Abstract][Full Text] [Related]
16. A bispecific antibody effectively inhibits tumor growth and metastasis by simultaneous blocking vascular endothelial growth factor A and osteopontin.
Kou G; Shi J; Chen L; Zhang D; Hou S; Zhao L; Fang C; Zheng L; Zhang X; Liang P; Zhang X; Li B; Guo Y
Cancer Lett; 2010 Dec; 299(2):130-6. PubMed ID: 20826049
[TBL] [Abstract][Full Text] [Related]
17. Osteopontin is involved in the formation of malignant pleural effusion in lung cancer.
Cui R; Takahashi F; Ohashi R; Yoshioka M; Gu T; Tajima K; Unnoura T; Iwakami S; Hirama M; Ishiwata T; Iwase A; Takahashi K
Lung Cancer; 2009 Mar; 63(3):368-74. PubMed ID: 18752867
[TBL] [Abstract][Full Text] [Related]
18. The elevated expression of osteopontin and vascular endothelial growth factor in sinonasal inverted papilloma and its relationship with clinical severity.
Liu W; Li Z; Luo Q; Lai Y; Zhang J; Chen F; Shi J; Li H; Xiong G; Xu G; Wang H
Am J Rhinol Allergy; 2011; 25(5):313-7. PubMed ID: 22186244
[TBL] [Abstract][Full Text] [Related]
19. Osteopontin inhibits macrophage nitric oxide synthesis to enhance tumor proliferation.
Wai PY; Guo L; Gao C; Mi Z; Guo H; Kuo PC
Surgery; 2006 Aug; 140(2):132-40. PubMed ID: 16904962
[TBL] [Abstract][Full Text] [Related]
20. SIBLINGs and SPARC families: their emerging roles in pancreatic cancer.
Kaleağasıoğlu F; Berger MR
World J Gastroenterol; 2014 Oct; 20(40):14747-59. PubMed ID: 25356037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
